Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

Obes Res. 2004 Oct;12(10):1658-69. doi: 10.1038/oby.2004.206.

Abstract

Objective: To examine the safety and efficacy of topiramate (TPM) for maintaining weight following a low-calorie diet.

Research methods and procedures: Obese subjects (30 < or = BMI < 50 kg/m(2)) 18 to 75 years old received a low-calorie diet for 8 weeks. Those who lost > or =8% of their initial weight received TPM (96 or 192 mg/d) or placebo; all were on a lifestyle modification plan. Sixty weeks of medication were planned. Sponsor ended study early to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. Efficacy was analyzed in subjects who completed 44 weeks of treatment before study termination.

Results: Of the 701 subjects enrolled, 80% lost > or =8% of their initial body weight and were randomized; 293 were analyzed for efficacy. Most withdrawals were due to premature termination of the study. Subjects receiving TPM lost 15.4% (96 mg/d) and 16.5% (192 mg/d) of their enrollment weight by week 44, compared with 8.9% in the placebo group (p < 0.001). Subjects on TPM continued to lose weight after the run-in, whereas those on placebo regained weight. Significantly more TPM subjects lost 5%, 10%, or 15% of their randomization weight than placebo. Most adverse events were related to the central nervous system.

Discussion: During a treatment period of 44 weeks, TPM was generally well tolerated, and subjects maintained weight loss initially achieved by a low-calorie diet-and produced additional clinically significant weight loss beyond that achieved by a low-calorie diet.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / therapeutic use*
  • Combined Modality Therapy / methods*
  • Diet, Reducing*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Fructose / adverse effects
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Obesity / diet therapy
  • Obesity / drug therapy*
  • Obesity / prevention & control
  • Paresthesia / chemically induced
  • Safety
  • Topiramate
  • Treatment Outcome
  • Weight Loss

Substances

  • Anti-Obesity Agents
  • Topiramate
  • Fructose